Genedrive PLC (AIM: GDR) has announced that its Genedrive® MT-RNR1 ID Kit has been implemented at Erasmus MC University Medical Center in Rotterdam, expanding the international adoption of its rapid pharmacogenetic testing technology.
The kit, which is designed to help prevent antibiotic-induced hearing loss in newborn babies, entered routine use at Erasmus MC on 3 August 2026.
Erasmus MC is one of Europe’s leading university medical centres and treats around 750 newborn babies each year in its neonatal intensive care unit. The implementation is being funded by the hospital’s Pharmacogenetics International Expert Center.
The test identifies newborns carrying the MT-RNR1 genetic variant, which can place them at risk of profound and irreversible hearing loss if treated with aminoglycoside antibiotics.
By delivering a rapid result at the point of care, the system allows clinicians to make informed prescribing decisions without delaying urgently needed treatment for suspected sepsis.
Chief executive Dr Gino Miele said the deployment strengthened Genedrive’s presence in Europe and reflected growing international recognition of the value of rapid pharmacogenetic testing.
Erasmus MC becomes the first medical centre in the Netherlands to introduce the technology into routine neonatal care.
The Genedrive® MT-RNR1 ID Kit is already in clinical use across more than 20 neonatal intensive care units in the UK and internationally, with further commercial and implementation activity progressing across Europe and the Middle East.
